Introduction
Medicis Pharmaceutical focuses on the development and marketing products for the treatment of dermatological, aesthetic and podiatric conditions in the US. It has branded prescription products in a number of therapeutic categories, including acne, fungal infections, psoriasis, rosacea, seborrheic dermatitis, and skin and skin-structure infections.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
The company is involved in developing and marketing dermatological and aesthetics products. Its current products are divided between the dermatological and non-dermatological fields. In the dermatological field it offers products such as Dynacin, Plexion, Solodyn, Triaz and Ziana for the treatment of acne and acne-related dermatological conditions Medicis generates its revenues from product sales and contracts. The company's total revenues increased at a CAGR of 13% during 2002-2006, from $213 million to $349 million. This represents an absolute growth of +$126 million during the historical period. Product sales were the largest contributor to the total revenue growth. Medicis' biggest contributor to sales growth out to 2010 will be the product sales (excluding Reloxin) and contract and licensing revenues. Revenues from these streams together are expected to contribute the entire +$368 million of absolute growth during the period 2006-2010.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
Report Highlights
[Studien Infos ausblenden]
